Whilst exact mechanisms remain unclear, a combination of risk factor reduction in improved HbA1c, weight, metabolic profile, as well as direct effects of GLP-1 agonism on coronary endothelial function and improved microvascular perfusion is likely at play
Thats what brings real, visible results over time
In published literature, combining a GHRH (like CJC-1295) with a GHRP (like Ipamorelin) produces a synergistic response that can result in a multi-fold increase in signal amplification compared to using either peptide alone
You get satisfied more quickly and stay full longer
It works by stimulating insulin release, suppressing excess glucagon, slowing gastric emptying, and reducing appetite
Thats why we often transition patients to a maintenance dose rather than stopping abruptly